Cargando…

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICPI) are a tumor agnostic treatment. However, trials of their use have been site specific. Here we summarize the trial data and explore the utility of programmed death-ligand 1 (PD-L1) expression as a biomarker to direct their pan-cancer use. METHOD: A syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fitzsimmons, Timothy S., Singh, Niharika, Walker, Thomas D. J., Newton, Claire, Evans, Dafydd G. R., Crosbie, Emma J., Ryan, Neil A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219231/ https://www.ncbi.nlm.nih.gov/pubmed/37250628 http://dx.doi.org/10.3389/fmed.2023.1192762

Ejemplares similares

The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta‐analysis
por: Atwal, Amit, et al.
Publicado: (2022)

Epithelial ovarian cancer risk: A review of the current genetic landscape
por: Flaum, Nicola, et al.
Publicado: (2019)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers
por: Romero, Joan Miguel, et al.
Publicado: (2023)

Efficacy and safety of combination PD‐1/PD‐L1 checkpoint inhibitors for malignant solid tumours: A systematic review
por: Yao, Qigu, et al.
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report
por: Goldman, Jonathan W., et al.
Publicado: (2018)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications
por: Hunter, Ewan, et al.
Publicado: (2023)

Tumor-Infiltrating PD-1(hi)CD8(+)-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
por: Yang, Zhenyu, et al.
Publicado: (2021)

Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer
por: Ryan, Neil A. J., et al.
Publicado: (2020)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)

HE4 as a Biomarker for Endometrial Cancer
por: Behrouzi, Roya, et al.
Publicado: (2021)

Current and Emerging Prognostic Biomarkers in Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2022)

BRCA and lynch syndrome-associated ovarian cancers behave differently
por: Ryan, Neil A.J., et al.
Publicado: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1
por: Flaum, Nicola, et al.
Publicado: (2023)

Analysis of biomarker utility using a PBPK/PD model for carbaryl
por: Phillips, Martin B., et al.
Publicado: (2014)

Cost-Effectiveness of the Manchester Approach to Identifying Lynch Syndrome in Women with Endometrial Cancer
por: Snowsill, Tristan M., et al.
Publicado: (2020)

A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?
por: Ryan, Neil A. J., et al.
Publicado: (2019)

Proteomic Biomarkers for the Detection of Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2019)

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors
por: Araujo-Fernandez, I., et al.
Publicado: (2020)

Immune Checkpoints in Solid Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2023)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_to88evqt5m3ca1bmhlq1a32bpm